These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Venci JV; Gandhi MA Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625 [TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS. Limmroth V Nat Rev Neurol; 2013 Jan; 9(1):8-10. PubMed ID: 23147843 [No Abstract] [Full Text] [Related]
7. Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis. Stangel M; Linker RA Expert Rev Clin Pharmacol; 2013 Jul; 6(4):355-62. PubMed ID: 23927662 [TBL] [Abstract][Full Text] [Related]
8. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT; N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073 [TBL] [Abstract][Full Text] [Related]
9. Another promising oral agent for multiple sclerosis. BMJ; 2012 Sep; 345():e6440. PubMed ID: 23044989 [No Abstract] [Full Text] [Related]
10. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT; N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072 [TBL] [Abstract][Full Text] [Related]
11. Fingolimod for multiple sclerosis. Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953 [TBL] [Abstract][Full Text] [Related]
12. Tecfidera(®): an approach for repurposing. Spencer RP Pharm Pat Anal; 2014 Mar; 3(2):183-98. PubMed ID: 24588595 [TBL] [Abstract][Full Text] [Related]
13. Dimethyl fumarate for treating relapsing multiple sclerosis. Sheremata W; Brown AD; Rammohan KW Expert Opin Drug Saf; 2015 Jan; 14(1):161-70. PubMed ID: 25382392 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Kappos L; Gold R; Miller DH; Macmanus DG; Havrdova E; Limmroth V; Polman CH; Schmierer K; Yousry TA; Yang M; Eraksoy M; Meluzinova E; Rektor I; Dawson KT; Sandrock AW; O'Neill GN; Lancet; 2008 Oct; 372(9648):1463-72. PubMed ID: 18970976 [TBL] [Abstract][Full Text] [Related]
15. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Kita M; Fox RJ; Phillips JT; Hutchinson M; Havrdova E; Sarda SP; Agarwal S; Kong J; Zhang A; Viglietta V; Sheikh SI; Seidman E; Dawson KT Mult Scler; 2014 Feb; 20(2):253-7. PubMed ID: 24150778 [TBL] [Abstract][Full Text] [Related]
17. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Kappos L; Gold R; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Sarda SP; Agarwal S; Zhang A; Sheikh SI; Seidman E; Dawson KT Mult Scler; 2014 Feb; 20(2):243-52. PubMed ID: 24150779 [TBL] [Abstract][Full Text] [Related]
18. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304 [TBL] [Abstract][Full Text] [Related]
19. Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use. Paik J CNS Drugs; 2021 Jun; 35(6):691-700. PubMed ID: 34057708 [TBL] [Abstract][Full Text] [Related]